Abstract
Herbal supplements are often used concomitantly with conventional medications resulting in considerable potential for herb-drug interactions. These interactions, which are generally through interfering with pharmacokinetic and/or pharmacodynamic pathways, may result in beneficial effects or more often adverse reactions such as toxicity or treatment failure and may be influenced by multiple environmental and/or genetic factors. The pharmacogenetic approach may help to identify some interactions which may be more pronounced or only occur in specific groups of subjects although the complex nature of the herbal medicines may limit the discovery of such an interaction. Preclinical studies such as gene expression profiling in rodent liver may help to define metabolic pathways influenced by herbal medicines and facilitate more accurate targeting of human in vivo studies. This review discusses the mechanisms of herb-drugs interaction and the potential influence of genetic variation on herb-drug interactions based on available clinical evidence.
Keywords: CYP450, drug transporter, genetic polymorphism, grape fruit juice, herb-drug interaction, pharmacogenetics, St John’s wort, herbal medicines, Herbal supplements, CYP enzymes
Current Pharmaceutical Biotechnology
Title:Herb-Drug Interactions: Methods to Identify Potential Influence of Genetic Variations in Genes Encoding Drug Metabolizing Enzymes and Drug Transporters
Volume: 13 Issue: 9
Author(s): M. Hu, D. Q. Wang, Y. J. Xiao, V. W. L. Mak and B. Tomlinson
Affiliation:
Keywords: CYP450, drug transporter, genetic polymorphism, grape fruit juice, herb-drug interaction, pharmacogenetics, St John’s wort, herbal medicines, Herbal supplements, CYP enzymes
Abstract: Herbal supplements are often used concomitantly with conventional medications resulting in considerable potential for herb-drug interactions. These interactions, which are generally through interfering with pharmacokinetic and/or pharmacodynamic pathways, may result in beneficial effects or more often adverse reactions such as toxicity or treatment failure and may be influenced by multiple environmental and/or genetic factors. The pharmacogenetic approach may help to identify some interactions which may be more pronounced or only occur in specific groups of subjects although the complex nature of the herbal medicines may limit the discovery of such an interaction. Preclinical studies such as gene expression profiling in rodent liver may help to define metabolic pathways influenced by herbal medicines and facilitate more accurate targeting of human in vivo studies. This review discusses the mechanisms of herb-drugs interaction and the potential influence of genetic variation on herb-drug interactions based on available clinical evidence.
Export Options
About this article
Cite this article as:
Hu M., Q. Wang D., J. Xiao Y., W. L. Mak V. and Tomlinson B., Herb-Drug Interactions: Methods to Identify Potential Influence of Genetic Variations in Genes Encoding Drug Metabolizing Enzymes and Drug Transporters, Current Pharmaceutical Biotechnology 2012; 13(9) . https://dx.doi.org/10.2174/138920112800958805
DOI https://dx.doi.org/10.2174/138920112800958805 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
An Efficient and Environmentally Benign Four-component Domino Protocol for Synthesis of Spirooxindoles Spiroannulated with Fused Heterosystems of Privileged Heterocycles
Current Bioactive Compounds Recognition of Nucleic Acid Ligands by Toll-Like Receptors 7/8: Importance of Chemical Modification
Current Medicinal Chemistry In-Vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models
Letters in Drug Design & Discovery COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Drug Targets for Rational Design against Emerging Coronaviruses
Infectious Disorders - Drug Targets Synthesis of Aminoalkoxy Substituted 4,5-Diphenylisoxazole Derivatives as Potential Anti-osteoporotic Agents
Medicinal Chemistry Comparative QSAR as a Cheminformatics Tool in the Design of Dihydro- Pyranone Based HIV-1 Protease Inhibitors
Current Computer-Aided Drug Design Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis, In Vitro and In Silico NS5B Polymerase Inhibitory Activity of Benzimidazole Derivatives
Medicinal Chemistry Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry The Study of the Biological Activity of Amino-Substituted Benzofuroxans
Letters in Drug Design & Discovery Dubious Results of Remdisivir Ultimately in Solidarity; Diversity of Severity of Illness is Doubtful
New Emirates Medical Journal Antibody Responses and CNS Pathophysiology of Mucormycosis in Chronic SARS Cov-2 Infection: Current Therapies Against Mucormycosis
Current Medicinal Chemistry Novel Coronavirus 2019 Outbreak: A Global Epidemic
Letters in Drug Design & Discovery Chitosan Oligomer and Zinc Oxide Nanoparticles for Treating Wastewaters: US20190134086 Patent Evaluation
Recent Patents on Biotechnology Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Meet Our Co-Editor
Current Psychopharmacology Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating
Current Medicinal Chemistry Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters